<unk>  is used in the treatment of HIV-1 infection, but is not a cure. It is not normally recommended as initial treatment.<unk>  can also reduce the risk of developing HIV-1 infection after coming into contact with the virus either at work (e.g., needlestick) or through exposure to infected blood or other bodily fluids. It is always used in combination with other HIV medications for the better control of the infection and a reduction in HIV complications. The World Health Organization (WHO) recommends<unk>  to be phased out to due to its high toxicity levels. If the drug must be used, it is recommended to use low dosages to reduce the occurrence of side effects; however, a 2015 Cochrane review found no clear advantage between high and low dosage regimens. Pregnancy and breastfeeding<unk>  has been demonstrated to affect the fetus in animal studies but no data are available from human studies. Pregnant women should therefore be given<unk>  only if the potential benefits outweigh the potential harm to the fetus. Additionally, there have been case reports of fatal lactic acidosis in pregnant women receiving combination therapy of<unk>  and didanosine with other antiviral agents. The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants, in order to avoid the risk of HIV transmission through breast milk. There is also evidence that<unk>  gets into animal breast milk, although no data are available for human breast milk. Children<unk>  is safe for use in children infected with HIV from birth through adolescence. Adverse effects and safety profile are the same as adults. Elderly There is no data available for<unk>  use in HIV-infected adults aged 65 years or older. However, among 12,000 people over the age of 65, 30% developed peripheral neuropathy. Additionally, since the elderly are more likely to have decreased renal function, they are more likely to develop toxic side effects.
Stavudine
Lamivudine
Censavudine
Saquinavir
Telbivudine
Sorivudine
Fostemsavir
Brivudine